✦ LIBER ✦

1146 POSTER Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom

✍ Scribed by F. Logman; B. Heeg; M.F. Botteman; A.A. Marfatia; B.A. van Hout

Book ID: 118625507
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 63 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70665-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost Effectiveness of Fracture Preventio

Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer

✍ Shih, Y.C.T.; Chien, C.R.; Shen, Y. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Economic evaluation of zoledronic acid f

Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in post-menopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom

✍ J.F.S. Logman; B.M.S. Heeg; M.F. Botteman; S. Kaura; B.A. van Hout 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

2008 POSTER The E-ZO-FAST trial: Zoledro

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

✍ N. Schenk; A. Lombart; A. Frassoladti; P. Neven; G. Jerusalem; I. Deleu; J. Mebi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Zoledronic acid (ZA) prevents aromatase

Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study

✍ A. Brufskv; L. Bosserman; R. Caradonna; B. Haley; M. Jones; H. Moore; M. Dong; G 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

P153 An integrated analysis of zoledroni

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; N. Bundred; R. Coleman; R. Lambert-Falls; R. Mena; M. Dong; N. Schen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB